debt_leverage_profile
Pre-revenue clinical-stage biotech; minimal debt, primarily equity-funded; likely net cash position with low leverage ratio
Inferred
Agent_Inference
interest_rate_sensitivity
Low direct sensitivity; higher rates increase cost of future equity raises and reduce biotech sector valuations broadly
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Gene therapy viral vector manufacturing (CDMOs like Lonza/Catalent) and specialized AAV capsid raw materials, both concentrated in EU/US
Inferred
Agent_Inference
international_expansion_readiness
Negligible international revenue; clinical-stage company with no commercial product; currency devaluation exposure effectively zero
Inferred
Agent_Inference
geographic_footprint
US-domiciled, early-stage; operations concentrated in single country; no material international revenue markets to assess
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single CDMO likely represents >50% of manufacturing input; AAV vector production is non-substitutable short-term without 12-18 month delay
Inferred
Agent_Inference
business_model_type_primary
Cloud infrastructure termination would disrupt internal R&D data pipelines and genomic analysis tools but not patient-facing operations
Inferred
Agent_Inference
business_model_type_secondary
Biotech R&D platform; cloud dependency moderate for bioinformatics; core IP in proprietary gene-editing platform, not cloud-hosted SaaS
Inferred
Agent_Inference
switching_cost_profile
Moderate API coupling risk via genomic databases and bioinformatics tools; proprietary wet-lab workflows reduce pure software lock-in
Inferred
Agent_Inference
howey_test_risk_index
Primary model is drug development/licensing; no securities-like token revenue; Howey Test not materially applicable
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited patient data exposure currently; clinical trial data governance under FDA/ICH GCP; GDPR risk low until EU trials scale
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; early-stage single-asset company with no market power; gene therapy market remains fragmented
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Pre-revenue; 100% transactional potential via future milestone payments and licensing deals; no recurring subscription revenue
Inferred
Agent_Inference
monetization_vector
Anticipated monetization via pharma partnership milestones, royalties, and potential asset sale or licensing of gene therapy platform
Inferred
Agent_Inference
pricing_architecture
No commercial pricing yet; future pricing likely cost-plus rare disease premium ($500K-$3M per treatment course based on gene therapy precedents)
Inferred
Agent_Inference
pricing_power_rating
High theoretical pricing power in rare disease gene therapy; single-administration curative model supports premium one-time pricing
Inferred
Agent_Inference
target_gross_margin_bracket
Target gross margin 70-85% at commercial scale typical for gene therapies after COGS normalization; near-term margins negative
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; gene therapy IP is proprietary and patent-protected; no open-source leakage pathway identified
Inferred
Agent_Inference
headcount_cost_structure
R&D headcount-linear through clinical phases; commercial launch would require significant headcount scaling; sublinear post-approval via partnerships
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth is high and capital-intensive through Phase 3; post-approval royalty/licensing model becomes highly scalable
Inferred
Agent_Inference
franchise_compliance_risk
No franchise network; not applicable to gene therapy biotech business model
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC economics depend on rare disease patient identification costs and KOL engagement; typically $50K-$200K per patient diagnosed
Inferred
Agent_Inference
network_effect_present
No traditional network effects; scientific data network effects possible via proprietary patient genomic database accumulation over time
Inferred
Agent_Inference
asset_efficiency_ratio
-29.9% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate-high recession resistance; rare disease treatments with no alternatives face inelastic demand; funding risk remains in downturns
Inferred
Agent_Inference
customer_segment_primary
Patients with rare genetic disorders; payer/reimbursement decisions made by large commercial insurers and government health programs
Inferred
Agent_Inference
customer_segment_secondary
Pharmaceutical/biotech licensing partners and academic medical centers serving as clinical trial sites and future commercial channels
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
51.7% CapEx / Revenue (High-CapEx Infrastructure)
High
SEC-XBRL
sec_cik
0001835579
High
SEC-EDGAR
ticker
IMA
High
SEC-EDGAR